Shoemaker Daniel D

Average Profitability
<0.0001%
Insider Buys Quantity
0
Insider Buys Sum
$0
Insider Sells Quantity
13
Insider Sells Sum
$9.9M

Insider Activity of Shoemaker Daniel D

The largest sale of all time was on 2020-11-16 and amounted to 50000 shares of Fate Therapeutics, Inc. for $2.59M.

Biography of Shoemaker Daniel D

No biography is available at this moment.

2021-03-08SaleFate Therapeutics, Inc.
FATE
Chief Scientific Officer
25,000
0.0276%
$81.74$2.04M-12.43%
2021-01-11SaleFate Therapeutics, Inc.
FATE
Chief Scientific Officer
3,253
0.0034%
$110.81$360,477-31.03%
2021-01-08SaleFate Therapeutics, Inc.
FATE
Chief Scientific Officer
6,229
0.0067%
$117.10$729,434-33.06%
2020-11-16SaleFate Therapeutics, Inc.
FATE
Chief Scientific Officer
50,000
0.0562%
$51.83$2.59M+56.34%
2020-09-14SaleFate Therapeutics, Inc.
FATE
Chief Scientific Officer
50,000
0.0558%
$36.30$1.82M+120.49%
2020-01-08SaleFate Therapeutics, Inc.
FATE
Chief Scientific Officer
11,400
0.0141%
$20.70$235,972+51.02%
2019-12-30SaleFate Therapeutics, Inc.
FATE
Chief Scientific Officer
50,000
0.0666%
$19.50$974,854+69.63%
2019-10-15SaleFate Therapeutics, Inc.
FATE
Chief Scientific Officer
23,600
0.0302%
$14.29$337,185+95.66%
2019-06-27SaleFate Therapeutics, Inc.
FATE
Chief Scientific Officer
25,000
0.0217%
$11.55$288,860+6.12%
2019-03-28SaleFate Therapeutics, Inc.
FATE
Chief Scientific Officer
25,000
0.0223%
$9.92$247,953+9.67%
2017-10-16SaleFate Therapeutics, Inc.
FATE
Chief Scientific Officer
1,400
0.0032%
$4.08$5,712+167.36%
2017-10-13SaleFate Therapeutics, Inc.
FATE
Chief Scientific Officer
25,050
0.0547%
$3.86$96,693+167.41%
2014-03-31SaleFate Therapeutics, Inc.
FATE
Chief Technology Officer
17,306
0.0856%
$9.86$170,722-46.46%
Company
About Prismo.proNewsPrivacy PolicyTerms of ServiceContact Us
Investing Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny Stocks
Stock Tools
Insiders ScreenerStocks ScreenerTop StocksList of All Stocks
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.